Clinical trials: Refractory Grade 2 Follicular Lymphoma

Lymphoma

Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab

• Completed
• Age: 18 years and older
• Phase 2
• Results posted

Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.

Trial name

NCT00238238

Testing

rituximab, lenalidomide

Where

79 sites in United States

Volunteers

97 people

Sponsor

Alliance for Clinical Trials in Oncology